Unknown

Dataset Information

Development of a Targeted SN-38-Conjugate for the Treatment of Glioblastoma.


ABSTRACT: Glioblastoma (GBM) is the most aggressive and fatal brain tumor, with approximately 10,000 people diagnosed every year in the United States alone. The typical survival period for individuals with glioblastoma ranges from 12 to 18 months, with significant recurrence rates. Common therapeutic modalities for brain tumors are chemotherapy and radiotherapy. The main challenges with chemotherapy for the treatment of glioblastoma are high toxicity, poor selectivity, and limited accumulation of therapeutic anticancer agents in brain tumors as a result of the presence of the blood-brain barrier. To overcome these challenges, researchers have explored strategies involving the combination of targeting peptides possessing a specific affinity for overexpressed cell-surface receptors with conventional c

SUBMITTER: Bataille Backer P 

PROVIDER: S-EPMC10795035 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature